|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Rivera F, Vega-Villegas ME and Lopez-Brea
MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev.
33:315–324. 2007. View Article : Google Scholar
|
|
3
|
Yazdani U and Terman JR: The semaphorins.
Genome Biol. 7:2112006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chilton JK and Guthrie S: Cranial
expression of class 3 secreted semaphorins and their neuropilin
receptors. Dev Dyn. 228:726–733. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giger RJ, Cloutier JF, Sahay A, et al:
Neuropilin-2 is required in vivo for selective axon guidance
responses to secreted semaphorins. Neuron. 25:29–41. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Falk J, Bechara A, Fiore R, et al: Dual
functional activity of semaphorin 3B is required for positioning
the anterior commissure. Neuron. 48:63–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nawabi H, Briancon-Marjollet A, Clark C,
et al: A midline switch of receptor processing regulates
commissural axon guidance in vertebrates. Genes Dev. 24:396–410.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tamagnone L and Comoglio PM: To move or
not to move? Semaphorin signalling in cell migration. EMBO Rep.
5:356–361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sekido Y, Bader S, Latif F, et al: Human
semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer
deletion region and demonstrate distinct expression patterns. Proc
Natl Acad Sci USA. 93:4120–4125. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tomizawa Y, Sekido Y, Kondo M, et al:
Inhibition of lung cancer cell growth and induction of apoptosis
after reexpression of 3p21.3 candidate tumor suppressor gene
SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tse C, Xiang RH, Bracht T and Naylor SL:
Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3
suppresses tumor formation in an adenocarcinoma cell line. Cancer
Res. 62:542–546. 2002.PubMed/NCBI
|
|
12
|
Tischoff I, Markwarth A, Witzigmann H, et
al: Allele loss and epigenetic inactivation of 3p21.3 in malignant
liver tumors. Int J Cancer. 115:684–689. 2005. View Article : Google Scholar
|
|
13
|
Ochi K, Mori T, Toyama Y, Nakamura Y and
Arakawa H: Identification of semaphorin3B as a direct target of
p53. Neoplasia. 4:82–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Castro-Rivera E, Ran S, Brekken RA and
Minna JD: Semaphorin 3B inhibits the phosphatidylinositol
3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer
cells. Cancer Res. 68:8295–8303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Castro-Rivera E, Ran S, Thorpe P and Minna
JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast
cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci
USA. 101:11432–11437. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koyama N, Zhang J, Huqun, et al:
Identification of IGFBP-6 as an effector of the tumor suppressor
activity of SEMA3B. Oncogene. 27:6581–6589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Varshavsky A, Kessler O, Abramovitch S, et
al: Semaphorin-3B is an angiogenesis inhibitor that is inactivated
by furin-like pro-protein convertases. Cancer Res. 68:6922–6931.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rolny C, Capparuccia L, Casazza A, et al:
The tumor suppressor semaphorin 3B triggers a prometastatic program
mediated by interleukin 8 and the tumor microenvironment. J Exp
Med. 205:1155–1171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
20
|
Vailaya A, Bluvas P, Kincaid R, Kuchinsky
A, Creech M and Adler A: An architecture for biological information
extraction and representation. Bioinformatics. 21:430–438. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li LC and Dahiya R: MethPrimer: designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gluzman-Poltorak Z, Cohen T, Herzog Y and
Neufeld G: Neuropilin-2 is a receptor for the vascular endothelial
growth factor (VEGF) forms VEGF-145 and VEGF-165. J Biol Chem.
275:299222000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soker S, Miao HQ, Nomi M, Takashima S and
Klagsbrun M: VEGF165 mediates formation of complexes containing
VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J
Cell Biochem. 85:357–368. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haiko P, Makinen T, Keskitalo S, et al:
Deletion of vascular endothelial growth factor C (VEGF-C) and
VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse
embryos. Mol Cell Biol. 28:4843–4850. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li K, Chen MK, Li LY, et al: The
predictive value of semaphorins 3 expression in biopsies for
biochemical recurrence of patients with low- and intermediate-risk
prostate cancer. Neoplasma. 60:683–689. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pronina IV, Loginov VI, Prasolov VS, et
al: Alteration of SEMA3B gene expression levels in epithelial
tumors. Mol Biol (Mosk). 43:439–445. 2009.(In Russian).
|
|
27
|
Riquelme E, Tang M, Baez S, et al:
Frequent epigenetic inactivation of chromosome 3p candidate tumor
suppressor genes in gallbladder carcinoma. Cancer Lett.
250:100–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuroki T, Trapasso F, Yendamuri S, et al:
Allelic loss on chromosome 3p21.3 and promoter hypermethylation of
semaphorin 3B in non-small cell lung cancer. Cancer Res.
63:3352–3355. 2003.PubMed/NCBI
|
|
29
|
Hesson L, Bieche I, Krex D, et al:
Frequent epigenetic inactivation of RASSF1A and BLU
genes located within the critical 3p21.3 region in gliomas.
Oncogene. 23:2408–2419. 2004.PubMed/NCBI
|
|
30
|
Bernal C, Vargas M, Ossandon F, et al: DNA
methylation profile in diffuse type gastric cancer: evidence for
hypermethylation of the BRCA1 promoter region in early-onset
gastric carcinogenesis. Biol Res. 41:303–315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bernal C, Aguayo F, Villarroel C, et al:
Reprimo as a potential biomarker for early detection in gastric
cancer. Clin Cancer Res. 14:6264–6269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Ma L, Li J, Gu J, Shi Q and Yu R:
Effects of SEMA3G on migration and invasion of glioma cells. Oncol
Rep. 28:269–275. 2012.PubMed/NCBI
|
